U.S. market Closed. Opens in 10 hours 1 minute

IRIX | IRIDEX Corporation Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.3900 - 1.4900
52 Week Range 1.3900 - 3.65
Beta 1.00
Implied Volatility 242.88%
IV Rank 80.68%
Day's Volume 37,097
Average Volume 24,864
Shares Outstanding 16,636,399
Market Cap 23,623,687
Sector Healthcare
Industry Medical - Devices
IPO Date 1996-02-16
Valuation
Profitability
Growth
Health
P/E Ratio -2.12
Forward P/E Ratio N/A
EPS -0.67
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 111
Country USA
Website IRIX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
*Chart delayed
Analyzing fundamentals for IRIX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see IRIX Fundamentals page.

Watching at IRIX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on IRIX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙